Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players’ financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Request Free Sample
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.
Speak to Analyst

Stem Cell Manufacturing Market Research Report Information by Product (Stem Cell Lines [Mesenchymal Stem Cells (MSCs), Induced Pluripotent Stem Cell (iPSC), Embryonic Stem Cell (ESC), Hematopoietic Stem Cells (HSCs), and Others], Instruments [Bioreactors, Incubators, Cell Sorters, and Others], Culture Media, and Consumables), by Application (Research, Target Identification, Stem Cell-Based Therapy [Autologous and Allogeneic], and Cell & Tissue Banking), by End User (Pharmaceutical & Biotechnology Companies, Hospitals, Stem Cell Banks, and O


ID: MRFR/LS/5477-CR | 116 Pages | Author: Kinjoll Dey| March 2023

Global Stem Cell Manufacturing Market Overview


The Stem Cell Manufacturing Market Size was valued at USD 10.64 billion in 2021 and is projected to grow from USD 12.02 billion in 2022 to USD 33.3 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 13.4% during the forecast period (2023 - 2032). The driving factors that are boosting market growth are growing awareness regarding the usage of stem cells for treating various diseases and the increasing prevalence of rare diseases.


Stem Cell Manufacturing MarketSource Secondary Research, Primary Research, MRFR Database and Analyst Review


The rising occurrence of rare illnesses and rising familiarity with stem cells as a treatment option are two factors fueling market expansion. The worldwide stem cell manufacturing industry is expanding at a dizzying rate, largely due to a growing public understanding of the therapeutic potential of stem cell products. At the same time, there are tremendous developments in stem cell research, and innovative approaches are revealed virtually year. This has resulted in a large influx of new workers into the industry, which has helped the stem cell manufacturing business explode.


In May 2023, to better understand how panCELLa's genetically engineered, induced Pluripotent Stem Cell (iPSC)-derived feeder cells can activate and positively impact the expansion rate, total yield, and potency of manufactured NK cells, BioCentriq, Inc. and panCELLa, a Pluristyx Company, signed a research agreement in May 2023. BioCentriq's goal is to assess viable cell production and potency under static and dynamic culture settings, and to employ the feeder cell bank as a reagent for activating adult and iPSC-derived NK cells. panCELLa designed the feeder line from iPSCs so that it could be easily adopted by treatment developers and their partners to help them overcome the difficulties of producing NK cell therapies.


Stem Cell Manufacturing Market Trends



  • Growing awareness regarding the usage of stem cells for treating various diseases boosts market growth


Stem cells help treat a wide range of incurable diseases such as acquired immune deficiency syndrome (AIDS), for which the treatments were previously unknown. Stem cell therapy also helps treat cardiovascular diseases, neurodegenerative diseases, autoimmune diseases, orthopedic conditions, and healing incisions & wounds. They are increasingly being utilized for replacing damaged neurons caused by spinal cord injuries, Parkinson's disease, Alzheimer's disease, and other neurological problems. They also produce insulin that supports in treatment of patients with diabetes and weak heart muscle and replaces the damaged tissue or the injured or diseased organ.


Moreover, rare diseases affect a small percentage of the population and are often neglected conditions whose treatments are often not considered profitable due to their cost to develop and limited patient population. Rare diseases include rare cancers, genetic diseases, infectious tropical diseases, and degenerative diseases. According to the data published by Food and Drug Administration (FDA) in February 2020, there were around 7,000 rare diseases, more than half of which affect children, and only 5% have FDA-approved treatments. Hence, increasing awareness associated with the usage of stem cells in treatment of various diseases and rising incidences of rare diseases propelling the growth of the market.


Stem Cell Manufacturing Market Segment Insights


Stem Cell Manufacturing Product Insights


The Market segments of Stem Cell Manufacturing, based on product, includes stem cell lines, instruments, culture media, and consumables. The stem cell lines segmented into mesenchymal stem cells (MSCs), induced pluripotent stem cell (iPSC), embryonic stem cell (ESC), hematopoietic stem cells (HSCs), and others moreover, instruments further segmented into bioreactors, incubators, cell sorters, and others. The stem cell lines segment accounted for the largest market share in 2021. The advent of stem cell research unveiled the therapeutic potential of stem cells and their derivatives and increased the awareness of the same in the public and scientific community. The successful manufacturing of stem cells and their derivatives has positively impacted medical sciences owing to its ever-expanding therapeutic solutions for patients is boosting the segment growth during the forecast period.


April 2021 Bristol-Myers Squibb Company (US) expands its business by building a new cell therapy manufacturing unit in the Netherlands. This expansion has given Bristol new opportunities.


Stem Cell Manufacturing Application Insights


The Stem Cell Manufacturing Market data has been segmented, based on application, by research, target identification, stem cell-based therapy, and cell & tissue banking. The stem cell-based therapy segment was anticipated to reach USD 4.84 billion by 2021. The stem cell based further bifurcated into autologous and allogeneic. Autologous stem cell therapy provides high compatibility with the human immune system, as the patients are their own donors of stem cells. For instance, in March 2021, Novadip Biosciences (Belgium) received approval from US FDA for the company’s Investigational New Drug (IND) application for its autologous cell therapy product NVD-003. Therefore, strategic alliances are propelling the growth of the segment.


October 2021 Bristol-Myers Squibb Company (US) announced positive topline results from phase 3 transform trial evaluating breyanzi versus chemotherapy followed by stem cell transplant in second-line relapsed or refractory large b-cell lymphoma.


Figure 2 Stem Cell Manufacturing Market, by Application, 2021 & 2030 (USD Billion)Stem Cell Manufacturing Market, by Application, 2021 & 2030Source Secondary Research, Primary Research, MRFR Database and Analyst Review


Stem Cell Manufacturing End User Insights


Based on end user, the global market of stem cell is segmented into hospitals, pharmaceutical, and biotechnology companies, stem cell banks, and others. The pharmaceutical, and biotechnology companies accounted for the largest market share in 2021. Pharmaceutical & biotechnology companies have taken an increased interest in stem cell biology. The use of stem cells as research tools has expanded, with most major pharmaceutical companies using embryonic stem cells (ESCs) or adult stem cells for internal drug discovery programs. These internal efforts are often enhanced through the expertise of external partnerships with academics or biotech companies which is bolstering the growth of the segment.


In June 2023, Bit.bio, a synthetic biology firm with a primary focus on human cells, has made significant progress in human cell manufacturing in June 2023. Bit.bio's induced pluripotent stem cell (iPSC)-derived cell products have attained a new level of accuracy and consistency thanks to their opti-oxTM 1-based transcription factor reprogramming technique. In order to produce the mature cell types, samples of cells were picked from various production lots and time periods, and the opti-ox reprogramming phase was performed by various users. Fewer than one percent of genes were found to have changed expression levels in bulk mRNA sequencing investigations comparing various batches of production. This breakthrough improves upon previous methods of producing human cells in the lab.


In July 2023, SCG Therapy was a forerunner in Singapore's Manufacturing 2030 Vision by opening a cell therapy manufacturing plant and research and development center. SCG's state-of-the-art cell therapy manufacturing and commercially available human induced Pluripotent Stem Cell (iPSC) technologies will be put to use and expanded upon at the new facility. SCG's state-of-the-art cell therapy manufacturing and commercially available human induced Pluripotent Stem Cell (iPSC) technologies will be put to use and expanded upon at the new facility. The facility will also serve as a distributor for cell therapy goods to hospitals in the Americas, Asia, and Europe.


In May 2023, StemCures, located in the United States, will open the largest stem cell production plant in India at its new facility in Telangana, India. The proposed facility would utilize cutting-edge American technology and know-how to produce high-quality stem cell products at competitive prices for the treatment of a wide range of life-threatening diseases. Currently, StemCures is finishing up Phase-1 lab trials for its stem cell line at the University of Hyderabad's Aspire Bionest.


Stem Cell Manufacturing Regional Insights


By Region, the study segments the market into North America, Europe, Asia-Pacific, and Rest of the World. North America stem cell manufacturing market accounted for the largest market share in 2021, due to increasing prevalence of chronic diseases such as cancer, cardiovascular disorders, neurological disorders, gastrointestinal diseases, other chronic conditions. In 2020, as per the National Cancer Institute, the National Institutes of Health forecasted an estimated 1,806,590 new cases of cancer to be diagnosed in the US, with about 606,520 deaths reported as a result of the disease.


Further, the major countries studied are The US, Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.


Figure 3 STEM CELL MANUFACTURING MARKET, BY REGION 2021 & 2030 (USD Billion)STEM CELL MANUFACTURING MARKET, BY REGION 2021 & 2030Source Secondary Research, Primary Research, MRFR Database and Analyst Review


Europe stem cell manufacturing market accounts for the second-largest market share due to the accessibility to advanced treatment facilities, support by government bodies for the development of the healthcare sector, the rising geriatric population, and the growing number of cases suffering from chronic and neurological disorders. Furthermore, the Germany market of stem cell manufacturing held the largest market share in 2021, and the UK market of stem cell manufacturing was the fastest growing market in the Europe region.


The Asia-Pacific stem cell manufacturing market is expected to grow at a significant share from 2022 to 2030 due to the factors such as improving healthcare infrastructure, growing adoption of stem cell therapy treatments, availability of contract manufacturers, and rising prevalence of cancer in the region, which are likely to drive the market’s growth. Moreover, China market of stem cell manufacturing held the largest market share, and the India market of stem cell manufacturing was the fastest growing market in the Asia-Pacific region.


Stem Cell Manufacturing Key Market Players & Competitive Insights


Major market players are spending a lot of money on R&D to increase their product lines, which will help the stem cell manufacturing market grow even more. Market participants are also taking a range of strategic initiatives to grow their worldwide footprint, including new product launches, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations. Competitors in the stem cell manufacturing industry must offer cost-effective items to expand and survive in an increasingly competitive and rising market environment.


Fujifilm Holdings Corporation (US) is the holding company of the Fujifilm Group, whose main business is in photographic films. Fujifilm has three operating companies headquartered in Japan Fuji Xerox Co., Ltd, FUJIFILM Corporation, and Toyama Chemical Co., Ltd. In January 2022, the company acquired a cell therapy manufacturing facility from Atara Biotherapeutics, Inc. (US), a leading allogeneic T-cell immunotherapy company, for USD 100 million. This acquisition is helping to Fujifilm Holdings Corporation (US) to expand its biosciences business.


Key Companies in the market of stem cell manufacturing includes.



  • Fujifilm Holdings Corporation (US)

  • AbbVie, Inc. (US)


  • Bio-Rad Laboratories, Inc. (US)


  • Becton, Dickinson, and Company (US)

  • Thermo Fisher Scientific, Inc. (US)

  • Lonza Group (Switzerland)

  • Bristol-Myers Squibb Company (US)

  • GlaxoSmithKline Plc (UK)

  • Sartorius AG (Germany)

  • Merck KGaA (Germany)

  • Others


Stem Cell Manufacturing Industry Developments


January 2022 Thermo Fisher Scientific Inc. (US) acquired PeproTech, Inc., (US), with a total cash purchase price of USD1,850 million. Cell & gene therapies and other cell culture applications utilize recombinant proteins in their development and manufacture.


March 2021 Fujifilm Holdings Corporation (US) contract development and manufacturing organization (CDMO), the US-based subsidiary, and Fujifilm Diosynth Biotechnologies (US) expanded its new manufacturing site with USD 2000 million cell culture facility in the North America region.


July 2020 Thermo Fisher Scientific Inc. (US) and Lyell Immunopharma (US) partnered to develop manufacturing procedures that resulted in more effective cell treatments for cancer patients. The company's major purpose is to improve T cell fitness and gain access to and knowledge of developing technologies.


Stem Cell Manufacturing Market Segmentation


Stem Cell Manufacturing Product Outlook



  • Stem Cell Lines

    • Mesenchymal Stem Cells (MSCs)

    • Induced Pluripotent Stem Cell (iPSC)

    • Embryonic Stem Cell (ESC)

    • Hematopoietic Stem Cells (HSCs)

    • Others



  • Instruments

    • Bioreactors

    • Incubators

    • Cell Sorters

    • Others



  • Culture Media

  • Consumables


Stem Cell Manufacturing Application Outlook



  • Research

  • Target Identification

  • Stem Cell-Based Therapy

    • Autologous

    • Allogenic



  • Cell & Tissue Banking


Stem Cell Manufacturing End User Outlook



  • Pharmaceutical & Biotechnology Companies

  • Hospitals

  • Stem Cell Banks

  • Others


Stem Cell Manufacturing Regional Outlook




  • North America



    • US

    • Canada




  • Europe



    • Germany

    • France

    • UK

    • Italy

    • Spain

    • Rest of Europe




  • Asia-Pacific



    • China

    • Japan

    • India

    • South Korea

    • Australia

    • Rest of Asia-Pacific




  • Rest of the World




    • Middle East




    • Africa




    • Latin America





Report Attribute/Metric Details
Market Size 2021 USD 10.64 billion
Market Size 2022 USD 12.02 billion
Market Size 2032 USD 33.3 billion
Compound Annual Growth Rate (CAGR) 13.4% (2023-2032)
Base Year 2021
Forecast Period 2023-2032
Historical Data 2018 & 2020
Forecast Units Value (USD Billion)
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Segments Covered Product, Application, End User, and Region
Geographies Covered North America, Europe, Asia Pacific, and Rest of the World
Countries Covered The US, Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil
Key Companies Profiled Fujifilm Holdings Corporation (US), AbbVie, Inc. (US), Bio-Rad Laboratories, Inc. (US), Becton, Dickinson and Company (US), Thermo Fisher Scientific, Inc. (US), Lonza Group (Switzerland), Bristol-Myers Squibb Company (US), GlaxoSmithKline Plc (UK), Sartorius AG (Germany), Merck KGaA (Germany) and Others
Key Market Opportunities Increasing public and private funding for stem cell-based research
Key Market Drivers Growing awareness regarding the usage of stem cells for treating various diseases Increasing prevalence of rare diseases


Frequently Asked Questions (FAQ) :

The Stem Cell Manufacturing Market is anticipated to reach 33.3 billion at a CAGR of 13.4% during the forecast period of 2023-2032.

The US is expected to hold a 85.80% share of the global market for stem cell manufacturing market during the forecast period of 2023-2032.

The stem cell manufacturing market is expected to grow at a 13.4% CAGR during the forecast period from 2023 to 2032.

The North America region market held the largest market share in stem cell manufacturing market.

The key players include Fujifilm Holdings Corporation (US), AbbVie, Inc. (US), Bio-Rad Laboratories, Inc. (US), Becton, Dickinson and Company (US), Thermo Fisher Scientific, Inc. (US), Lonza Group (Switzerland), Bristol-Myers Squibb Company (US), GlaxoSmithKline Plc (UK), Sartorius AG (Germany), Merck KGaA (Germany) and Others.

The stem cell lines product led the stem cell manufacturing market.

Stem cell-based therapy application segment had the largest market share.

Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Kindly complete the form below to receive a free sample of this Report
Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Request Free Sample
Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.
Ask for Customization